Skip to content

Share Buybacks at other companies

Vera Therapeutics logo
Vera TherapeuticsVERA
$0-100%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$19.76M+97.5%
AbbVie logo
AbbVieABBV
$1.49B+54.9%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$82.5M+70.9%
Alkermes logo
AlkermesALKS
$27.7M
Abbott logo
AbbottABT
$180M-35.7%

Other financials

Income statement

See full
Revenue$77.7M+24.4%
Gross profit$71.2M+32.1%
Operating income$41.4M+89.6%
Net income$34.4M+47.2%
EPS (diluted)$0.25+56.3%

Balance sheet

See full
Cash & equivalents$41.0M-38.3%
Total debt$85.2M-7.9%
Total equity$567.6M+62.1%
Total assets$724.0M+43.4%

Cash flow

See full
Operating cash flow$32.6M+2,405%

Valuation

See full
Market cap$2.39B+78.5%

Profitability

See full
Gross margin89.7%+1.5pp
Operating margin41.7%+29.4pp
Net margin100%+83.9pp

Returns & leverage

See full
Return on equity65%+53.8pp
Debt / equity0.2×-0.1×
Current ratio5.5×-0.4×

Where this comes from

Reported directly by Aurinia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock.

The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aurinia Pharmaceuticals's share buybacks.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aurinia Pharmaceuticals's share buybacks?
Aurinia Pharmaceuticals (AUPH) reported share buybacks of $36.17M in Q1 2026.
How has Aurinia Pharmaceuticals's share buybacks changed year-over-year?
Aurinia Pharmaceuticals's share buybacks decreased by 22.9% year-over-year, from $46.92M to $36.17M.
What does share buybacks mean?
Cash used to buy back the company's own shares on the open market or through structured programs, reducing shares outstanding.